Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

Zhouqing Chen1 Department of Neurosurgery, The First Affiliated Hospital of Soochow Unicersity, Suzhou, Jiangsu Province 215006, China, [email protected]

Na Xu2 State Key Laboratory of Medical Neurobiology, Institute of Brain Sciences and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai 200032, China

Chongshun Zhao1 Department of Neurosurgery, The First Affiliated Hospital of Soochow Unicersity, Suzhou, Jiangsu Province 215006, China, [email protected]

Tao Xue1 Department of Neurosurgery, The First Affiliated Hospital of Soochow Unicersity, Suzhou, Jiangsu Province 215006, China, [email protected]

Xin Wu1 Department of Neurosurgery, The First Affiliated Hospital of Soochow Unicersity, Suzhou, Jiangsu Province 215006, China, [email protected]

Zhong Wang1 Department of Neurosurgery, The First Affiliated Hospital of Soochow Unicersity, Suzhou, Jiangsu Province 215006, China, [email protected]Correspondence[email protected]

Pages 2193-2205 | Published online: 23 Jul 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BurriSHGondiVBrownPDMehtaMPThe Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for OncologistsAm J Clin Oncol201841219119628832384
PubMed Web of Science ®Google Scholar
de PascalisIMorganteLPacioniSEndothelial trans-differentiation in glioblastoma recurring after radiotherapyMod Pathol Epub2018
PubMed Web of Science ®Google Scholar
PoulsenHSUrupTMichaelsenSRStabergMVillingshøjMLassenUThe impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patientsCancer Manag Res2014637338725298738
PubMed Web of Science ®Google Scholar
OmuroABealKMcneillKMulticenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic GliomasJ Clin Oncol201836171702170929683790
PubMed Web of Science ®Google Scholar
ShergalisABankheadA3rdLuesakulUMuangsinNNeamatiNCurrent Challenges and Opportunities in Treating GlioblastomaPharmacol Rev201870341244529669750
PubMed Web of Science ®Google Scholar
BronnimannCIzquierdoCCartalatSRechallenge with bevacizumab in patients with glioblastoma progressing off therapyJ Neurooncol2018138114114529388033
PubMed Web of Science ®Google Scholar
dasSMarsdenPAAngiogenesis in glioblastomaN Engl J Med2013369161561156324131182
PubMed Web of Science ®Google Scholar
FineHABevacizumab in glioblastoma–still much to learnN Engl J Med2014370876476524552324
PubMed Web of Science ®Google Scholar
HundsbergerTReardonDAWenPYAngiogenesis inhibitors in tackling recurrent glioblastomaExpert Rev Anticancer Ther201717650751528438066
PubMed Web of Science ®Google Scholar
FieldKMJordanJTWenPYRosenthalMAReardonDABevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesCancer20151217997100725263092
PubMed Web of Science ®Google Scholar
JakobsenJNHasselbalchBStockhausenMTLassenUPoulsenHSIrinotecan and bevacizumab in recurrent glioblastoma multiformeExpert Opin Pharmacother201112582583321385110
PubMed Web of Science ®Google Scholar
OlsonJJNayakLOrmondDRThe role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guidelineJ Neurooncol2014118355759924740195
PubMed Web of Science ®Google Scholar
WickWGorliaTBendszusMLomustine and Bevacizumab in Progressive GlioblastomaN Engl J Med2017377201954196329141164
PubMed Web of Science ®Google Scholar
NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
PubMed Web of Science ®Google Scholar
BalanaCde Las PenasRSepúlvedaJMBevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialJ Neurooncol2016127356957926847813
PubMed Web of Science ®Google Scholar
CloughesyTFinocchiaroGBelda-IniestaCRandomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker AnalysesJ Clin Oncol201735334335127918718
PubMed Web of Science ®Google Scholar
WeathersSPHanXLiuDDA randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaJ Neurooncol2016129348749427406589
PubMed Web of Science ®Google Scholar
FieldKMSimesJNowakAKRandomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaNeuro Oncol201517111504151326130744
PubMed Web of Science ®Google Scholar
TaalWOosterkampHMWalenkampAMSingle-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialLancet Oncol201415994395325035291
PubMed Web of Science ®Google Scholar
FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
PubMed Web of Science ®Google Scholar
TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
PubMed Web of Science ®Google Scholar
YangSBGaoKDJiangTChengSJLiWBWbLBevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trialsOncotarget2017834573375734428915674
PubMedGoogle Scholar
LiYHouMLuGCicconeNWangXZhangHThe Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled TrialsPLoS One20161112e016826428005980
PubMed Web of Science ®Google Scholar
duCRenJZhangREffect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical TrialsMed Sci Monit2016223486349227684457
PubMed Web of Science ®Google Scholar
AlkhaliliKZenonosGFernandez-MirandaJCDo Corticosteroids Compromise Survival in Glioblastoma?Neurosurgery2016794N15N1627635969
PubMed Web of Science ®Google Scholar
PitterKLTamagnoIAlikhanyanKCorticosteroids compromise survival in glioblastomaBrain2016139Pt 51458147127020328
PubMed Web of Science ®Google Scholar
MoherDLiberatiATetzlaffJAltmanDGThe PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: The PRISMA StatementPLoS Med200966e100009719621072
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date